ST elevation myocardial infarction recurrent ischemia/infarction

(Redirected from Recurrent heart attack)
Jump to navigation Jump to search

Acute Coronary Syndrome Main Page

ST Elevation Myocardial Infarction Microchapters

Home

Patient Information

Overview

Pathophysiology

Pathophysiology of Vessel Occlusion
Pathophysiology of Reperfusion
Gross Pathology
Histopathology

Causes

Differentiating ST elevation myocardial infarction from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Natural History and Complications

Risk Stratification and Prognosis

Pregnancy

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples

Chest X Ray

Cardiac MRI

Echocardiography

Coronary Angiography

Treatment

Pre-Hospital Care

Initial Care

Oxygen
Nitrates
Analgesics
Aspirin
Beta Blockers
Antithrombins
The coronary care unit
The step down unit
STEMI and Out-of-Hospital Cardiac Arrest
Pharmacologic Reperfusion
Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI)
Fibrinolysis
Reperfusion at a Non–PCI-Capable Hospital:Recommendations
Mechanical Reperfusion
The importance of reducing Door-to-Balloon times
Primary PCI
Adjunctive and Rescue PCI
Rescue PCI
Facilitated PCI
Adjunctive PCI
CABG
Management of Patients Who Were Not Reperfused
Assessing Success of Reperfusion
Antithrombin Therapy
Antithrombin therapy
Unfractionated heparin
Low Molecular Weight Heparinoid Therapy
Direct Thrombin Inhibitor Therapy
Factor Xa Inhibition
DVT prophylaxis
Long term anticoagulation
Antiplatelet Agents
Aspirin
Thienopyridine Therapy
Glycoprotein IIbIIIa Inhibition
Other Initial Therapy
Inhibition of the Renin-Angiotensin-Aldosterone System
Magnesium Therapy
Glucose Control
Calcium Channel Blocker Therapy
Lipid Management

Pre-Discharge Care

Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT

Post Hospitalization Plan of Care

Long-Term Medical Therapy and Secondary Prevention

Overview
Inhibition of the Renin-Angiotensin-Aldosterone System
Cardiac Rehabilitation
Pacemaker Implantation
Long Term Anticoagulation
Implantable Cardioverter Defibrillator
ICD implantation within 40 days of myocardial infarction
ICD within 90 days of revascularization

Case Studies

Case #1

Case #2

Case #3

Case #4

Case #5

ST elevation myocardial infarction recurrent ischemia/infarction On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ST elevation myocardial infarction recurrent ischemia/infarction

CDC on ST elevation myocardial infarction recurrent ischemia/infarction

ST elevation myocardial infarction recurrent ischemia/infarction in the news

Blogs on ST elevation myocardial infarction recurrent ischemia/infarction

Directions to Hospitals Treating ST elevation myocardial infarction

Risk calculators and risk factors for ST elevation myocardial infarction recurrent ischemia/infarction

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Reinfarction is defined as a recurrence of a myocardial infarction. The rate of reinfarction on angiography (15-20% following fibrinolytic administration) is higher than the clinical rate of reinfarction (2% to 6%) in the setting of ST elevation myocardial infarction.

Definitions

Clinical Predictors and Timing of Reinfarction Following Fibrinolytic Administration

The frequency, timing, and clinical predictors of in-hospital reinfarction were evaluated in the Global Utilization of Streptokinase and Tissue plasminogen activator (alteplase) for Occluded coronary arteries (GUSTO I) and Global Use of Strategies To Open occluded coronary arteries (GUSTO III) populations [1]. Reinfarction developed in in 2,258 out of 55, 911 patients (4.3%). Reinfarction was diagnosed a median of 3.8 days after fibrinolytic administration. The specific fibrinolytic agent administered was not associated with the rate of reinfarction: streptokinase, 4.1%; alteplase, 4.3%; reteplase, 4.5%; combined streptokinase and alteplase, 4.4%; P=0.55. Multivariate predictors or reinfarction included the following: older age, shorter time to fibrinolytic administration, non-US enrollment, nonsmoking status, prior MI or angina, female gender, anterior MI, and lower systolic blood pressure.

Angiographic Predictors of Reinfarction Following Fibrinolytic Administration

Gibson et al documented that angiographically confirmed reocclusion is observed more frequently among culprit arteries with TIMI grade 2 versus TIMI grade 3 flow (10.4% vs. 2.2%, p = 0.003), in ulcerated lesions (10.7% vs. 3.0%, p = 0.009) and in the presence of collateral vessels (18.2% vs. 5.6%, p = 0.03). Trends toward higher rates of reocclusion were observed among eccentric (7.3% vs. 2.3%, p = 0.06) and thrombotic (8.4% vs. 3.3%, p = 0.06) lesions. Reocclusion was associated with a more severe percent diameter stenosis on quantitative coronary angiography (77.9% vs. 73.9%, p = 0.04).[2]. Pulsatile flow or reversal of flow during systole has been associated with a higher rate of reinfarction [3].

Prognosis of Reinfarction Following Fibrinolytic Administration

In the combined GUSTO I and III experience, reinfarction was associated with a higher mortality at 30 days(11.3% versus 3.5% without reinfarction; odds ratio, 3.5; P<0.001) and from 30 days to 1 year (4.7% versus 3.2%; hazard ratio, 1.5; P<0.001). Significant multivariate predictors of in-hospital death or reinfarction included older age, higher Killip class, lower systolic and diastolic blood pressures, higher heart rate, the presence of an anterior MI, smoking, a history of prior MI, gender, and country of enrollment (all P<0.001) [1]. In contrast, Gibson et al did not find an increase in mortality between 30 days and 2 years in over 20,000 patients in the TIMI trials [4]. Higher mortality at 2 years was found to be due to an early divergence in mortality by 30 days and was not due to a significant increase in late mortality between 30 days and 2 years (4.38% [31/707] vs. 3.76% [685/18,206], p = NS).

Strategies to Reduce Reinfarction Following Fibrinolytic Administration

Gibson et al reported in their analysis of over 20,000 patients from the TIMI trials that percutaneous coronary intervention performed at the time of the index hospitalization was associated with a lower rate of in-hospital recurrent MI (1.6% vs. 4.5%, p < 0.001) and lower two-year mortality (5.6% vs. 11.6%, p < 0.001). Likewise, coronary artery bypass graft (CABG) surgery was also associated with a lower rate of recurrent MI (0.7% vs. 4.3%, p < 0.001) as well as a lower two-year mortality rate (7.95% vs. 10.6%, p = 0.0008).

2004 ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (DO NOT EDIT)[5]

Class I
"1. Patients with recurrent ischemic-type chest discomfort after initial reperfusion therapy for STEMI should undergo escalation of medical therapy with nitrates and beta-blockers to decrease myocardial oxygen demand and reduce ischemia. Intravenous anticoagulation should be initiated if not already accomplished. (Level of Evidence: B)"
"2. In addition to escalation of medical therapy, patients with recurrent ischemic-type chest discomfort and signs of hemodynamic instability, poor LV function, or a large area of myocardium at risk should be referred urgently for cardiac catheterization and undergo revascularization as needed. Insertion of an IABP should also be considered. (Level of Evidence: C)"
"3. Patients with recurrent ischemic-type chest discomfort who are considered candidates for revascularization should undergo coronary arteriographyand PCI or CABG as dictated by coronary anatomy. (Level of Evidence: B)"
Class III
"1. Streptokinase should not be readministered to treat recurrent ischemia/infarction in patients who received a non–fibrin-specific fibrinolytic agent more than 5 days previously to treat the acute STEMI event. (Level of Evidence: C)"
Class IIa
"1. It is reasonable to (re)administer fibrinolytic therapy to patients with recurrent ST elevation and ischemictype chest discomfort who are not considered candidates for revascularization or for whom coronary angiography and PCI cannot be rapidly (ideally less than 60 minutes from the onset of recurrent discomfort) implemented. (Level of Evidence: C)"

Sources

  • The 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction [5]

References

  1. 1.0 1.1 Hudson MP, Granger CB, Topol EJ; et al. (2001). "Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials". Circulation. 104 (11): 1229–35. PMID 11551872. Unknown parameter |month= ignored (help)
  2. Gibson CM, Cannon CP, Piana RN; et al. (1995). "Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial". J. Am. Coll. Cardiol. 25 (3): 582–9. PMID 7860900. Unknown parameter |month= ignored (help)
  3. Gibson CM, Karha J, Murphy SA; et al. (2004). "Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction". J. Am. Coll. Cardiol. 43 (7): 1170–6. doi:10.1016/j.jacc.2003.11.035. PMID 15063425. Unknown parameter |month= ignored (help)
  4. Gibson CM, Karha J, Murphy SA; et al. (2003). "Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials". J. Am. Coll. Cardiol. 42 (1): 7–16. PMID 12849652. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK (2004). "ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)". Circulation. 110 (9): e82–292. PMID 15339869. Unknown parameter |month= ignored (help)

Template:WH Template:WS